Marcel Braun

Dr. Marcel Braun

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2024 in Current Sleep Medicine Reports
Verified
Journal Article
Open access
PDF file
MBMarcel Braun
Marcel Braun
MSM. Stockhoff
M. Stockhoff
MTM. Tijssen
M. Tijssen
SDS. Dietz-Terjung
S. Dietz-Terjung
SCS. Coughlin
S. Coughlin
CSC. Schöbel
C. Schöbel
Purpose of Review: The increasing demand for sleep diagnostic studies represents a challenge for many healthcare systems. Home polysomnography (hPSG), either set up by a technician or self-applied by the patient, provides comprehensive sleep signals and has the potential to replace in-lab sleep studies in a large number of cases.The aim of this study is to assess the existing evidence regarding the technical feasibility of hPSG in a systematic review. A systematic literature search was conducted in MEDLINE, PubMed, and Google Scholar to identify relevant research. Using a priori-defined inclusion criteria, studies were reviewed by three researchers, and a quality assessment was conducted. Relevant data were extracted, and the pooled failure rate with hPSG was computed. Additional subgroup analyses were conducted to further assess factors influencing technical feasibility. Recent Findings: Thirty studies totaling 14,465 patients were included (mean sample size 482 ± 1289 participants). Common deployment models for hPSG were at-home application by a technician (58%) and technician-led in-hospital set-up (31%), followed by at-home self-application by the patient (11%). Technical failure rate across the studies ranged from 0 to 23.4%, with a pooled failure rate of 7.8% (95% CI 5.5–10.1%). Depending on deployment models, failure rates varied slightly. Failures of hPSG were largely related to signal acquisition. No studies reported adverse events from hPSG. Patient preferences were assessed by eleven studies, with 56% (range 22–95%) preferring hPSG over in-lab recording. Summary: Based on the research identified for this review, home PSG is safe and technically feasible with relatively low failure rates. Further research is required to better understand decision-making with this tool in comparison to other sleep diagnostic procedures.

24 June 2023 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Open access
PDF file
MBMarcel Braun
Marcel Braun
MSManuel Stoerzel
Manuel Stoerzel
MWMathias Wollny
Mathias Wollny
CSChristoph Schoebel
Christoph Schoebel
JSJ. Ulrich Sommer
J. Ulrich Sommer
CHClemens Heiser
Clemens Heiser
Introduction: Hypoglossal nerve stimulation (HNS) has recently been introduced as an alternative treatment for patients with OSA. A large number of studies have demonstrated substantial changes in OSA with this therapy by reducing respiratory events and improving symptoms such as daytime sleepiness and quality of life. The objective of this review was to conduct a systematic review and meta-analysis to evaluate patient-reported outcomes and experience with HNS therapy. Methods: A systematic literature search of MEDLINE, Cochrane, and Web of Science was performed to identify randomized controlled and observational studies reporting subjective outcomes with different HNS systems in patients with OSA. Abstracts of 406 articles were screened and a subset of 55 articles were reviewed for eligibility. Risk of bias was assessed using the ROBINS-I tool. Meta-analysis using RevMan was performed when > 2 studies were identified that reported data on a specific outcome. Results: Thirty-four publications reporting data on 3785 patients with a mean follow-up of 11.8 ± 12.2 months were identified and included in the meta-analysis. The analysis revealed a pooled effect of 4.59 points improvement in daytime sleepiness as measured by the ESS questionnaire (Z = 42.82, p < .001), 2.84 points improvement in daytime functioning as measured by the FOSQ score (Z = 28.38, p < .001), and 1.77 points improvement in sleep quality as measured by the PSQI questionnaire (Z = 2.53, p = .010). Patient-reported experience was consistently positive and revealed additional relevant aspects from this perspective. Conclusion: HNS therapy significantly improves quality of life in patients with OSA and reliably produces clinically meaningful effects on daytime sleepiness, daytime functioning, and sleep quality. Treatment regularly meets or exceeds the minimum clinically important differences defined for the respective instruments. Additional research is needed to further investigate effects on quality of life beyond improvements in daytime sleepiness and daytime functioning.

Verified
Journal Article
Open access
PDF file
MWMathias Wollny
Mathias Wollny
CHClemens Heiser
Clemens Heiser
JSJ. Ulrich Sommer
J. Ulrich Sommer
CSChristoph Schöbel
Christoph Schöbel
MBMarcel Braun
Marcel Braun
Background/Objectives: Hypoglossal nerve stimulation (HNS) emerged as an alternative treatment for patients with obstructive sleep apnea (OSA) a decade ago. Long-term clinical trials and real-world data show that HNS treatment provides significant and sustained improvements in both OSA disease control and quality-of-life measures over time. Given the nature of HNS treatment, with the requirement of using an implantable neurostimulation system, patient safety is a critical domain in the assessment of this technology. The objective of this review was to evaluate adverse events (AEs) and complications with HNS therapy in a systematic review of published evidence. Methods: Medline, Cochrane, and Web of Science were systematically searched to identify randomized controlled and real-world observational studies reporting relevant outcomes with HNS therapy for treatment of OSA that included procedure-, device-, and treatment-related AEs. Results: Out of 418 articles screened, 27 were reviewed for eligibility, and 17 studies, the majority found to have low-to-moderate risk of bias, with data on 1962 patients were included for further analysis. Across included studies, reporting of AEs was heterogeneous with regard to the classifications used and the extent of reporting. Over an average follow-up duration of 17.5 ± 16.9 months, the pooled mortality rate was 0.01% (95% CI = 0.0 to 0.2%), with all reported deaths being unrelated to HNS treatment. The HNS system survival probability over the follow-up time of 60 months was 0.9834 (95% CI = 0.9768 to 0.9882), with infections and request for removal by patients being the most common indications. The pooled surgical revision rate was 0.08% (95% CI 0.0 to 0.2%). Most reported treatment-related side effects were transient stimulation-related discomfort (0.08%, 95% CI = 0.0 to 0.2%) and tongue abrasions (0.07%, 95% CI = 0.0 to 0.2%). Based on the systematic review, a standardized set of endpoints was defined, aiming to harmonize safety data relevant to HNS therapy. Conclusions: In this systematic review, HNS therapy for treatment of OSA is associated with a positive patient safety profile. AEs occur mainly at device implantation and during the treatment acclimatization period. Due to a lack of available evidence, partially implantable HNS systems are underrepresented in this review, which limits the generalizability of the results. Significant heterogeneity was found for adverse event reporting. A framework for reporting HNS outcomes that includes AEs and side effects is proposed to facilitate comparability of the reported data.

10 November 2021 in Somnologie
Verified
Journal Article
Closed access
PDF file
MBMarcel Braun
Marcel Braun
SDSarah Dietz-Terjung
Sarah Dietz-Terjung
CTChristian Taube
Christian Taube
CSChristoph Schoebel
Christoph Schoebel

10 January 2022 in Sleep and Breathing
Verified
Journal Article
Closed access
PDF file
MBMarcel Braun
Marcel Braun
SDSarah Dietz-Terjung
Sarah Dietz-Terjung
CTChristian Taube
Christian Taube
CSChristoph Schoebel
Christoph Schoebel

5 August 2023 in Sleep and Breathing
Verified
Journal Article
Open access
PDF file
MBMarcel Braun
Marcel Braun
MWM. Wollny
M. Wollny
CSC. Schoebel
C. Schoebel
JSJ. U. Sommer
J. U. Sommer
CHC. Heiser
C. Heiser
Background: Breathing-synchronized hypoglossal nerve stimulation (HNS) is routinely used as an alternative treatment for patients with obstructive sleep apnea (OSA). Significant and clinically relevant improvements in disease severity and OSA symptoms such as daytime sleepiness as well as overall quality of life have been reported in randomized-controlled trials and large real-world cohort studies. However, so far, few data exist on patient-reported experience with the treatment. Methods: A structured survey with 22 questions was constructed using five-level Likert scales (1 = no agreement, 5 = complete agreement) to evaluate patient experience with HNS and perception of the treatment in the domains “Overall experience with therapy,” “Experience with treatment process,” and “Side-effects from treatment.” Additional data were collected on current symptom status, measured with Epworth sleepiness scale (ESS) questionnaire, and OSA disease history. Multiple linear regression analysis was conducted to test associations of medical variables and response behavior. Correlations between variables and domains, as well as individual items, were assessed using Spearman rank test. Results: A total of 75 patients from Germany who were treated with breathing-synchronized HNS were enrolled (mean age 57.3 years, 78% male), and 71 questionnaires with complete data were included for analysis. Two-thirds of participants (67%) had a history of OSA history for 5 years or longer. Of all patients, 76% had normalized OSA symptoms at time of the study (ESS: 6.4 ± 5.0) and 98% reported using stimulation therapy every night. Regression analysis revealed an association of current symptoms measured with ESS and response behavior. Hence, patients with normalized daytime sleepiness reported significantly more positive experience across all domains assessed, compared to patients with residual daytime sleepiness. Overall, only 2% of participants reported side effects that made them reduce or discontinue stimulation therapy. The rate of reported side effects was associated with current symptom control under therapy. Conclusions: Overall patient-reported experience with breathing-synchronized HNS therapy was positive and high satisfaction with the treatment process was observed. Side effects occurred, but rarely affected subjective use of the therapy or satisfaction. Subjective experience and perception are influenced by residual daytime sleepiness with stimulation therapy.